Lilly, PhRMA Challenge FDA's Reliance on Randomized Trials for Rare Diseases

Share

Eli Lilly and pharmaceutical industry groups are urging FDA to move beyond conventional randomized clinical trials and provide clearer, more consistent standards for evaluating rare disease treatments, warning that the agency's review practices may not reflect its publicly stated commitment to regulatory flexibility.

In comments posted to FDA's docket on statistical considerations for rare disease clinical investigations, Lilly, the Biotechnology Innovation Organization (BIO) and PhRMA called for greater acceptance of alternative statistical approaches, external controls and corroborating evidence when traditional trials are impractical or unethical.

Lilly offered particularly pointed criticism of FDA's 9/29 RISE workshop, saying discussions repeatedly emphasized reasons to retain randomized concurrent controls rather than examining how alternative approaches could produce reliable evidence.

The company argued that the workshop's emphasis appeared inconsistent with FDA's October 2026 Rare Disease Framework, which acknowledges that conventional placebo-controlled trials may be infeasible in small patient populations.

Lilly asked FDA to take five actions, including establishing circumstances in which relaxed statistical significance thresholds would be acceptable, providing durable agreements on clinical endpoints, and creating a pre-pivotal agreement mechanism covering Bayesian statistical approaches and borrowing rules.

The company also urged FDA to explain its reasoning when declining regulatory flexibility in individual product reviews and to propose feasible alternatives.

PhRMA similarly argued that randomized controlled trials should be considered one option among several, rather than the preferred design in every rare disease development program.

The organization supported context-specific adjustments to statistical success criteria, including consideration of significance thresholds less stringent than conventional standards when scientifically justified and supported by corroborating evidence.

PhRMA also urged FDA to consider the totality of evidence, including biological plausibility, natural history, biomarkers and consistency across clinical endpoints, rather than relying exclusively on a single statistically significant result.

BIO endorsed alternative statistical success criteria when prospectively specified and scientifically justified. It encouraged greater use of Bayesian methods, adaptive trial designs, external evidence and real-world data, while calling for clearer guidance and consistent implementation across FDA review divisions.

The ALS Association, in a separate submission, took a more cautious position on statistical thresholds. It opposed broadly lowering success criteria simply because a disease is rare and supported retaining randomized trials when feasible and ethical.

Nevertheless, the association endorsed adaptive and platform trials, shared controls, fit-for-purpose biomarkers and external evidence. It also urged FDA to use amyotrophic lateral sclerosis research, including brain-computer interface technologies, as a model for modernizing rare disease regulatory science.

The comments respond to FDA's September request for information and its RISE workshop examining the balance between statistical reliability, trial feasibility and the urgency of developing treatments for patients with serious rare diseases.

The comments are available in docket FDA-2026-N-10165:

Read more